Is precision treatment of KRAS mutant NSCLC advancing? What is the best strategy?
Prof. Dr. I. Demedts, AZ Delta, Roeselare
Dr. A. Sibille, CHU de Liège
Dr. L. Pirard, CHU UCL Namur, Godinne
Dr. A. Sibille, CHU de Liège
Dr. L. Pirard, CHU UCL Namur, Godinne
© Janssen-Cilag NV 2021. This site is published by Janssen-Cilag NV which is solely responsible for its content. It is intended for Healthcare professionals in Belgium and Luxembourg.
